
真菌免疫调节蛋白基因LZ-8过表达载体的构建及转化灵芝原生质体的研究
孙墨可,张曼,田娟,李晓薇,李海燕,李玉
菌物学报 ›› 2017, Vol. 36 ›› Issue (12) : 1625-1631.
真菌免疫调节蛋白基因LZ-8过表达载体的构建及转化灵芝原生质体的研究
Construction of an overexpression vector containing LZ-8 gene and transformation of Ganoderma lingzhi protoplasts
灵芝Ganoderma lingzhi是我国著名的药用真菌。但是,作为一种营养和保健价值都非常高的大型担子菌,灵芝还缺乏完善的转基因方法和安全转基因体系。本研究建立了免疫调节蛋白基因的过表达系统,并利用真菌特异性启动子GPD、终止子NOS和目的基因LZ-8构建真菌特异性双T-DNA表达载体 pSB130NG-LZ8;利用溶壁酶提取灵芝原生质体,并用FDA染色法检测灵芝原生质体活性,原生质体成活率约为80%。通过PEG转化法对灵芝原生质体成功进行了转化,转化得到的原生质体在带有潮霉素抗性平板上长出,转化率为3-4/μg pSB130NG-LZ8+107个原生质体。转化子通过PCR检测和荧光定量PCR检测,获得LZ-8在灵芝中的过表达。
Ganoderma lingzhi is a famous medicinal fungus in China. However, as one of the basidiomycetes with high nutritional and biological value, G. lingzhi still lacks a perfect method for transgenesis and a safe transgenic system. In this study, an overexpression system for regulating immune proteins was established, and a fungus-specific double-stranded T-DNA expression vector pSB130NG-LZ8 was constructed using fungus-specific promoter GPD, terminator NOS and target gene LZ-8. Protoplasts were isolated from G. lingzhi with lywallzymes, and protoplast activity of G. lingzhi was determined by FDA staining. Survival rate of protoplasts was about 80%. Protoplasts of G. lingzhi were successfully transformed by PEG-mediated transformation, and the transformed protoplasts grew on the plate with hygromycin resistance. Transformation rate was about 3-4/μg pSB130NG-LZ8 + 107 protoplasts. Transformants were confirmed to be overexpressed in G. lingzhi by PCR and fluorescent quantitative PCR.
灵芝 / 双T-DNA载体 / 目的基因LZ-8 / PEG转化法 / 荧光定量PCR {{custom_keyword}} /
Ganoderma lingzhi / T-DNA binary vector / target gene LZ-8 / PEG mediated transformation / fluorescent quantitation PCR {{custom_keyword}} /
表1 所用引物及序列Table 1 Primer sequences used for PCR amplification |
引物名称 Primer name | 序列 Sequence (5′-3′) |
---|---|
GPD-F | GCTCTAGACGTTCGTGACTCGCAATATC |
GPD-R | CGGGATCCTGCGGGTGAAAGAGGAGG |
LZ-8-F | TCCTCGAGTACAACTCCGGG |
LZ-8-R | CGGGGTACCTGCCTCCTCCTAGTTCCAC |
NOS-F | TCCTCGAGTACAACTCCG |
NOS-R | CCTGGATCGTGTTTGTCC |
HygB-F | ATCGTTATGTTTATCGGCACT |
HygB-R | ATGTTGGCGACCTCGTATT |
[1] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[2] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[3] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[4] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[5] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[6] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[7] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[8] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[9] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[10] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[11] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[12] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[13] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[14] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[15] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[16] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[17] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[18] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[19] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[20] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[21] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[22] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[23] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[24] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[25] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 |
|
〉 |